Agenus Inc. EV/FCF

EV/FCF of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of Agenus Inc. is -21.49 (as of December 30, 2019)
  • EV/FCF for the quarter ending June 29, 2020 was -4.48 (a 116.75% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -57.48%
  • Annual EV/FCF for 2019 was -21.49 (a 1192.58% increase from previous year)
  • Annual EV/FCF for 2018 was -1.66 (a -64.17% decrease from previous year)
  • Annual EV/FCF for 2017 was -4.64 (a 3.06% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Agenus Inc.

Most recent EV/FCFof AGEN including historical data for past 10 years.

Interactive Chart of EV/FCF of Agenus Inc.

Agenus Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -4.48 -2.07
2019 -21.49 -10.55 -12.5 -13.43 -21.49
2018 -1.66 -1.82 -1.77 -3.46 -1.66
2017 -4.64 -5.99 -4.63 -4.29 -4.64
2016 -4.5 -7.11 -4.24 -4.31 -4.5
2015 -5.87 -7.05 -16.72 -9.64 -5.87
2014 -4.95 -4.49 -4.95 -3.65 -4.95
2013 -2.95 -5.18 -7.69 -7.88 -2.95
2012 122.26 12530.27 467.32 -456.62 122.26
2011 -4.01 -5.42 -7.5 -8.52 -4.01
2010 -7.55 -7.2 -5.32 -4.48 -7.55
2009 -2.88 0.0 -2.88

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.